Results 1,381-1,400 of 1,954 for speaker:John Gilroy
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: That is inaccurate.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: How can Senator Barrett say that? Has the Senator an insight into this?
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: Section 5.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I was trying to assist the Senator.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: That is good for the Senator.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: It has to be adopted first.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I welcome the Minister of State. I welcome Senator MacSharry's call that the Bill be debated in a non-party political and calm manner. I will be led by the Senator in that regard. I am quite certain that Senators Darragh O'Brien, Crown and Barrett do not intend to disrespect their colleagues in the House by suggesting that the Minister of State's contribution has been spoon-fed to her by...
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: The script has been proofed by one Dr. Susan O'Reilly of the NCCP over whose credentials Senator John Crown might stand. Before the Senator gets on his high horse and insults the Minister of State, Senator Colm Burke and me for being spoon-fed, the well thought out element of the Bill is not all on the one side. I suggest the Bill is not too well thought out at all. Section 3 seeks to...
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: Is the health budget limited if we spend X plus â¬1 in one area we must spend X minus â¬1 in another area? The other area could equally be as life threatening as the first. There is a responsibility on the Government, the Department of Health and the HSE to set appropriate priorities and make decisions in the interest of the entire population. This Bill undermines that responsibility....
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I did not say there is no example anywhere in the world.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I said my research has failed to identify such an example.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I am not saying it has not ever been done.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I appreciate the protection the Chair is giving me from the unreasonable heckling from the other side of the House, which seems to possess the totality of knowledge on this matter. Section 3 seems to allow all "medicinal products necessary for the treatment of cancer, as approved by the European Medicines Agency" to be prescribed by a "registered medical practitioner". I suggest this is at...
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: How come I only have one minute remaining?
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I thank the Chair. The European Medicines Agency approves new drugs for sale but it does not play a role in deciding the most effective-----
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I thought the Leader of the House said on the Order of Business this morning that spokespersons would have eight minutes.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: I suggest that if we agree to this proposal, we might build a cost into certain drugs and products, as providers will be conscious of the statutory obligation on the health service to provide these products. Therefore, the effect of this Bill could be exact opposite of its intent. When a new drug is introduced, its price generally falls when it is widely produced. If there is a statutory...
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: A little more thought needs to be put into it.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: That is not true.
- Seanad: Access to Cancer Treatment Bill 2012: Second Stage (11 Jul 2012)
John Gilroy: Where is that in the text of the Bill?